Multi-Ethnic Study of Atherosclerosis (MESA)

StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv13
  2. Notable Primary and study completion dates: Dec 2024 to Dec 2030v12
  3. Re-verified, no change to tracked fieldsv11
  4. Notable Primary and study completion dates: Dec 2019 to Dec 2024v10
  5. Notable Primary and study completion dates pushed to Dec 2019v9 Show 4 more changesShow less
    • Enrollment target: estimated 6000 to confirmed 6418
    • Eligibility criteria expanded, about 11 words
    • Study description shortened, about 1,411 words
    • Publications: 172 to 79
Show 7 earlier versionsHide 7 earlier versions
  1. Re-verified, no change to tracked fieldsv8
  2. Minor Study completion date changed from estimate of Aug 2015 to Jun 2009
    • Study description expanded, about 22 words
    v7
  3. Minor Publications: 173 to 172v6
  4. Re-verified, no change to tracked fieldsv5
  5. Minor Enrollment target: 6000
    • Primary completion date: Aug 2015
    • Publications: 80 to 173
    v4
  6. Minor Study completion date: Jan 2009 to Aug 2015v3
  7. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,870 trials monitored
See 440 trials at risk
5,141 trials monitored
See 246 trials at risk
3,560 trials monitored
See 169 trials at risk
and 4 more diseases
The Multi-Ethnic Study of Atherosclerosis (MESA) is a study of the characteristics of subclinical cardiovascular disease and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical disease (Bild DE et al., Am J Epidemiol 2002; 156(9):871-881). MESA consists of a diverse, community-based sample of an initial 6,814 men and women aged 45-84 years without known cardiovascular disease at baseline. Thirty-eight percent of the recruited participants were White, 28 percent African American, 22 percent Hispanic, and 12 percent of Chinese descent. Participants were recruited from six field centers across the United States: Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; New York, New York; and St. Paul, Minnesota. Participants are being followed for identification and characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart disease (CHD), stroke, and heart failure; for cardiovascular disease interventions; and for mortality. The first examination took place over two years, from July 2000 to July 2002, and has been followed by additional examinations. Participants have been contacted every 9 to 12 months throughout the study to assess and adjudicate clinical morbidity and mortality. The study was approved by the Institutional review boards at all participating institutions, and all participants gave written informed consent. In addition, informed consent was obtained for extensive data sharing (dbGaP) and genetic/omic studies, including candidate genes (NHLBI CARe), genome-wide scans (NHLBI SHARe), exome sequencing (NHLBI ESP) and, most recently, the NHLBI TOPMed program.
Trial Details
NCT Number NCT00005487
Lead Sponsor National Heart, Lung, and Blood Institute (NHLBI)
Conditions
(from sponsor)
Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Coronary Disease, Stroke, Myocardial Infarction, Heart Failure +3 more
Related terms Atherosclerosis, Cardiovascular Diseases, Coronary Artery Disease, Coronary Disease, Diabetes Mellitus, Diabetes Mellitus, Type 2, Heart Diseases, Heart Failure, Hypertension, Myocardial Infarction, Stroke
Enrollment 6,418 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov